about
Direct cardiac effects of intracoronary bupivacaine, levobupivacaine and ropivacaine in the sheepTesting protein leverage in lean humans: a randomised controlled experimental studyMaternal cigarette smoke exposure contributes to glucose intolerance and decreased brain insulin action in mice offspring independent of maternal dietRole of central nervous system glucagon-like Peptide-1 receptors in enteric glucose sensingBrain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats.Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver.PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly.AMP-activated protein kinase activation by AICAR increases both muscle fatty acid and glucose uptake in white muscle of insulin-resistant rats in vivo.APPL1 potentiates insulin-mediated inhibition of hepatic glucose production and alleviates diabetes via Akt activation in mice.Liver-specific deletion of insulin receptor substrate 2 does not impair hepatic glucose and lipid metabolism in mice.Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin.Oral administration of glucose promotes intracellular partitioning of fatty acid toward storage in white but not in red muscle.Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requires a functional glucagon-like peptide 1 receptor.Rosiglitazone Treatment Enhances Acute AMP-Activated Protein Kinase-Mediated Muscle and Adipose Tissue Glucose Uptake in High-Fat-Fed RatsC3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet
P50
Q28346463-7F37A76E-9ABD-450D-B1BC-D96F86ECBA92Q28743959-EACA52B5-F7B9-45F3-8E90-42D16BF253C8Q34072678-4E05EB6D-AF4E-4B44-A917-1C7D51711DD8Q36906311-C3880C6B-12DB-4BE1-B895-867177F18E54Q40035788-9BC86D90-27DD-4041-85C3-0DCF3B71DFE4Q44155454-F5FAA2FF-766E-467C-AA1D-BA53F61C1989Q44225982-7BD01095-BB14-4895-B51B-3B539EDE03C7Q44295528-5F304E73-830C-45E1-9DE3-3701DEBF2E04Q44953897-ADC609B6-D3B1-4460-BACD-EFB534EB4ECAQ46024901-D7EA0048-22FB-4051-8777-F924258F7AD3Q46888113-5B8CFD90-15F1-4848-B24A-20BED0948B7AQ46925729-DFDC4F4F-504E-43F1-AD26-3BAEB6A45D79Q50720068-CB38F114-A157-44B8-9294-FFB2F35833CFQ51498948-B29183C7-BD16-449B-B8C8-E41DCF1B35FEQ57817324-B9FF627B-C86E-49A1-B706-F32198719F0EQ58106596-35775E23-195C-4B63-ADF6-ABC16121BD17
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Miguel A Iglesias
@ast
Miguel A Iglesias
@en
Miguel A Iglesias
@es
Miguel A Iglesias
@nl
Miguel A Iglesias
@sl
type
label
Miguel A Iglesias
@ast
Miguel A Iglesias
@en
Miguel A Iglesias
@es
Miguel A Iglesias
@nl
Miguel A Iglesias
@sl
prefLabel
Miguel A Iglesias
@ast
Miguel A Iglesias
@en
Miguel A Iglesias
@es
Miguel A Iglesias
@nl
Miguel A Iglesias
@sl
P1053
J-7879-2014
P106
P21
P31
P3829
P496
0000-0001-5781-2091